Search Results

ACN Accenture plc - Fundamental Analysis

NEUTRAL
Sign in to save Save this symbol to a watchlist or track a position.
ACN Stock | Fundamental Analysis & Investment Insights
NYSE Technology Information Technology Services
Current Price Live
$281.07
Analyst Target
$291.42
+3.7% Upside
52W High
$398.35
52W Low
$229.4

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Jan 24, 2026
Market cap
$174.3B
P/E
23.58
ROE
25.0%
Profit margin
10.8%
Debt/Equity
0.26
Dividend yield
2.29%

AI Analysis

Powered by advanced machine learning algorithms

Confidence Score
72%
Analysis Accuracy
Accenture's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial health, while the absence of an Altman Z-Score prevents a full distress risk assessment. Despite solid profitability metrics like a 25.02% ROE and manageable 0.26 Debt/Equity ratio, earnings growth is weakening with a -1.60% YoY decline and bearish insider activity. The stock trades at a significant premium to its Graham Number of $115.99 and intrinsic value of $83.44, currently priced at $281.07, though it remains below the analyst target of $291.42. Mixed signals from strong historical earnings beats (3 out of last 4 quarters) and recent positive EPS growth contrast with deteriorating technical trends and negative insider sentiment.

Key Strengths

Strong return on equity (25.02%) indicating efficient use of shareholder capital
Consistently beats earnings estimates, with 3 out of last 4 quarters showing positive surprises
Low leverage with Debt/Equity ratio of 0.26, suggesting conservative capital structure
Solid operating cash flow generation implied by high operating margin (16.97%)
Attractive dividend yield of 2.29% with sustainable 50.17% payout ratio

Key Risks

Weak Piotroski F-Score of 4/9 signals potential financial instability and operational inefficiencies
Earnings declining YoY (-1.60%) and QoQ (-3.00%), raising concerns about near-term profitability
Bearish technical trend (0/100) and price down 21.9% over the past year
Insider selling activity totaling $2.11M in the last 6 months, signaling lack of confidence
Significant valuation premium: trading at $281.07 vs Graham Number of $115.99 and intrinsic value of $83.44
AI Fair Value Estimate
Based on comprehensive analysis
$115.99
-58.7% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
56
Moderate
Value
35
Future
50
Past
75
Health
52
Dividend
70
AI Verdict
Neutral with upside risk if growth reaccelerates
Key drivers: High profitability metrics, Weak earnings growth, Bearish insider activity, Premium valuation, Stable balance sheet
Confidence
70%
Value
35/100

Ref P/E, PEG, Graham Number

Positives
  • Lower forward P/E of 18.88 suggests improving valuation outlook
Watchpoints
  • Current P/E of 23.58 above sector average despite lower growth
  • Price/Sales of 2.46 not justified by 6% revenue growth
  • Stock trades at 2.4x Graham Number ($115.99)
Future
50/100

Ref Growth rates

Positives
  • Recent Q/Q EPS growth of +30.0% indicates potential rebound
  • Analyst target price implies 3.7% upside
Watchpoints
  • Revenue growth slowing at 6.00% YoY
  • Earnings declining YoY (-1.60%) and QoQ (-3.00%)
Past
75/100

Ref Historical trends

Positives
  • 22 out of 25 quarters beat or meet earnings estimates
  • Long-term track record of consistent earnings delivery
  • Average earnings surprise of +4.29% over last 4 quarters
Watchpoints
  • Most recent quarter missed estimates (-0.9%)
Health
52/100

Ref Altman Z-Score, Piotroski F-Score

Positives
  • Current ratio of 1.41 and quick ratio of 1.29 indicate adequate liquidity
  • Debt/Equity of 0.26 is conservative
Watchpoints
  • Piotroski F-Score of 4/9 indicates weak financial health
  • Altman Z-Score unavailable, limiting distress risk analysis
Dividend
70/100

Ref Yield, Payout

Positives
  • Dividend yield of 2.29% above market average
  • Payout ratio of 50.17% is sustainable
  • Dividend strength score of 50/100 indicates moderate reliability
Watchpoints
  • No 5-year average yield data to assess consistency

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$281.07
Analyst Target
$291.42
Upside/Downside
+3.7%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for ACN and closest competitors.

Updated 2026-01-23
Company 5Y 3Y 1Y 6M 1M 1W
ACN
Accenture plc
Primary
+19.4% +6.6% -21.9% -0.7% +4.1% -1.8%
TXN
Texas Instruments Incorporated
Peer
+26.8% +19.6% +5.6% -10.1% +9.8% +0.7%
ADI
Analog Devices, Inc.
Peer
+143.3% +101.1% +48.0% +41.8% +16.4% +5.3%
QCOM
QUALCOMM Incorporated
Peer
+8.4% +41.9% +1.0% +4.1% -7.5% -10.3%
ANET
Arista Networks, Inc.
Peer
+609.0% +347.9% +5.6% +19.3% +4.3% +5.0%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
23.58
Forward P/E
18.88
PEG Ratio
N/A
P/B Ratio
5.6
P/S Ratio
2.46
EV/Revenue
2.44
EV/EBITDA
13.85
Market Cap
$174.3B

Profitability

Profit margins and return metrics

Profit Margin 10.76%
Operating Margin 16.97%
Gross Margin 31.97%
ROE 25.02%
ROA 11.12%

Growth

Revenue and earnings growth rates

Revenue Growth +6.0%
Earnings Growth -1.6%
Q/Q Revenue Growth N/A
Q/Q Earnings Growth -3.0%

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.26
Low debt
Current Ratio
1.41
Good
Quick Ratio
1.29
Good
Cash/Share
$15.69

Quarterly Earnings History

EPS performance vs analyst estimates

2026-03-19
$N/A
2025-12-18
$3.94
+5.9% surprise
2025-09-25
$3.03
+2.0% surprise
2025-06-20
$3.49
+5.0% surprise

Technology Sector Comparison

Comparing ACN against 149 companies in the Technology sector (11 bullish, 67 neutral, 71 bearish)
P/E Ratio
23.58
This Stock
vs
80.58
Sector Avg
-70.7% (Discount)
Return on Equity (ROE)
25.02%
This Stock
vs
-6.46%
Sector Avg
-487.0% (Below Avg)
Profit Margin
10.76%
This Stock
vs
-9.26%
Sector Avg
-216.2% (Weaker)
Debt to Equity
0.26
This Stock
vs
0.7
Sector Avg
-63.2% (Less Debt)
Revenue Growth
6.0%
This Stock
vs
61.74%
Sector Avg
-90.3% (Slower)
Current Ratio
1.41
This Stock
vs
3.39
Sector Avg
-58.4% (Weaker)

Similar Companies

Peer comparison within the same industry

Company AI Rating Market Cap P/E ROE Profit Margin Price
ACN
Accenture plc
NEUTRAL $174.3B 23.58 25.0% 10.8% $281.07
TXN
Texas Instruments Incorporated
NEUTRAL $174.17B 34.96 29.8% 29.2% $191.58
ADI
Analog Devices, Inc.
BEARISH $173.84B 78.2 7.9% 23.0% $355.03
QCOM
QUALCOMM Incorporated
NEUTRAL $172.01B 31.88 23.3% 12.5% $159.42
ANET
Arista Networks, Inc.
NEUTRAL $171.69B 52.64 31.7% 39.7% $136.34

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

Date Insider Position Transaction Shares Value
2026-01-20 CLIFFORD KATHERINE LEE Officer Sale 681 $191,108
2026-01-14 SHARMA MANISH Officer Sale 2,731 $786,871
2026-01-14 MACCHI MAURO Officer Sale 500 $140,000
2026-01-14 SWEET JULIE SPELLMAN Chief Executive Officer Sale 1,694 $488,380
2026-01-07 MACCHI MAURO Officer Sale 500 $140,000
2026-01-06 UNRUCH JOEL SCOTT General Counsel Sale 1,332 $366,300
2026-01-05 WALSH JOHN F Officer Stock Award 1,760 $27,364
2026-01-05 UNRUCH JOEL SCOTT General Counsel Stock Award 1,431 $27,627
2026-01-05 SHARMA MANISH Officer Stock Award 1,173 $18,418
2026-01-05 PARK ANGIE Y Chief Financial Officer Stock Award 1,097 $27,627
2026-01-05 CLIFFORD KATHERINE LEE Officer Stock Award 538 $17,365
2026-01-05 HOGAN CATHERINE KIERNAN Chief Operating Officer Stock Award 914 $21,312
2026-01-05 BURGUM MELISSA A Officer Stock Award 674 $19,997
2026-01-05 SWEET JULIE SPELLMAN Chief Executive Officer Stock Award 3,477 $38,678
2025-12-31 WALSH JOHN F Officer Stock Award 5,192 -
Insider transactions can signal confidence or concerns about company prospects

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
BUY
27 analysts
Wells Fargo
2026-01-14
Maintains
Equal-Weight Equal-Weight
Truist Securities
2026-01-06
init
Buy
UBS
2025-12-19
Maintains
Buy Buy
Susquehanna
2025-12-19
Maintains
Neutral Neutral
RBC Capital
2025-12-19
Maintains
Outperform Outperform
Morgan Stanley
2025-12-16
up
Equal-Weight Overweight
Citigroup
2025-10-22
init
Neutral
Wells Fargo
2025-10-22
init
Equal-Weight
Mizuho
2025-09-29
Maintains
Outperform Outperform
BMO Capital
2025-09-26
Maintains
Market Perform Market Perform

Past News Coverage

Recent headlines mentioning ACN from our newsroom.

Newest → oldest
TradingGPT V1 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Dashboard AI Chat Analysis Charts Profile